Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study
Evidence regarding the role, if any, of dietary and lifestyle factors in the pathogenesis of multiple sclerosis (MS) is poorly understood.
To assess the effect of lifestyle-based risk factors linked to cardiovascular disease (CVD) on clinical and MRI-derived MS outcomes.
The study enrolled 175 MS or clinically isolated syndrome (CIS) patients and 42 age- and sex-matched healthy controls (HCs) who were longitudinally followed for 5.5 years. The 20-year CVD risk was calculated by Healthy Heart Score (HHS) prediction model which includes age, smoking, body mass index, dietary intake, exercise, and alcohol consumption. Baseline and follow-up MRI scans were obtained and cross-sectional and longitudinal changes of T2-lesion volume (LV), whole brain volume (WBV), white matter volume (WMV), gray matter volume (GMV), and lateral ventricular volume (LVV) were calculated.
After correcting for disease duration, the baseline HHS values of the MS group were associated with baseline GMV (rs = − 0.20, p = 0.01), and longitudinal LVV change (rs = 0.19, p = 0.01). The association with LVV remained significant after adjusting for baseline LVV volumes (rs = 0.2, p = 0.008) in MS patients. The diet component of the HHS was associated with the 5-year T2-LV accrual (rs = − 0.191, p = 0.04) in MS. In the HC group, the HHS was associated with LVV (rs = 0.58, p < 0.001), GMV (rs = − 0.57, p < 0.001), WBV (rs = − 0.55, p = 0.001), T2-LV (rs = 0.41, p = 0.027), and WMV (rs = − 0.38, p = 0.042). Additionally, the HC HHS was associated with the 5-year change in LVV (rs = 0.54, p = 0.001) and in WBV (rs = − 0.45, p = 0.011).
Lifestyle risk factors contribute to accelerated central brain atrophy in MS patients, whereas unhealthier diet is associated with MS lesion accrual. Despite the lower overall effect when compared to HCs, lifestyle-based modifications may still provide a beneficial effect on reducing brain atrophy in MS patients.
KeywordsMRI MS Lifestyle Exercise Smoking Diet Alcohol T2-lesions Central brain atrophy
We wish to acknowledge all study participants and investigators that were involved and contributed to the CEG-MS study over the period of 8 years.
Compliance with ethical standards
Conflicts of interest
This study was funded in part by The Annette Funicello Research Fund for Neurological Diseases and internal resources of the Buffalo Neuroimaging Analysis Center. In addition, we received support from the Jacquemin Family Foundation. Research reported in this publication was also funded in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award Number UL1TR001412. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dejan Jakimovski, Sirin Gandhi,Yi Guan, Jesper Hagemeier, Deepa P. Ramasamy, Tom Fuchs, Richard Browne, Niels Bergsland, Michael Dwyer have nothing to disclose. Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis and Acorda. Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals,, EMD Serono, Genzyme&Sanofi, Novartis, Acorda. Murali Ramanathan received research funding the National Multiple Sclerosis Society, the National Institutes of Health and Otsuka Pharmaceutical and Development. These are unrelated to the research presented in this report. Robert Zivadinov received personal compensation from EMD Serono, Genzyme-Sanofi, Claret Medical, Celgene and Novartis for speaking and consultant fees. He received financial support for research activities from Genenetech, Genzyme-Sanofi, Novartis, and Quintiles/IMS.
Ethical approval for research involving human participants and/or animals
The study was approved by the University at Buffalo Institutional Review Board (IRB) and all participants signed written informed consent.
- 5.University of California SFMSET, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Budingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL (2016) Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 80(4):499–510. https://doi.org/10.1002/ana.24747 Google Scholar
- 6.Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, Patten SB, Svenson LW, Tremlett H, Fisk J, Blanchard JF, Epidemiology, CTi, Impact of Comorbidity on Multiple S (2012) Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler 18(9):1310–1319. https://doi.org/10.1177/1352458512437814 Google Scholar
- 10.Jakimovski D, Gandhi S, Paunkoski I, Bergsland N, Hagemeier J, Ramasamy DP, Hojnacki D, Kolb C, Benedict RHB, Weinstock-Guttman B, Zivadinov R (2018) Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. Eur J Neurol. https://doi.org/10.1111/ene.13769 Google Scholar
- 12.Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R (2016) Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 87(2):181–187. https://doi.org/10.1136/jnnp-2014-310051 Google Scholar
- 14.Marrie RA, Patten SB, Tremlett H, Wolfson C, Warren S, Svenson LW, Jette N, Fisk J, Epidemiology, CTit, Impact of Comorbidity on Multiple S (2016) Sex differences in comorbidity at diagnosis of multiple sclerosis: a population-based study. Neurology. https://doi.org/10.1212/WNL.0000000000002481 Google Scholar
- 15.Magalhaes S, Pugliatti M, Casetta I, Drulovic J, Granieri E, Holmoy T, Kampman MT, Landtblom AM, Lauer K, Myhr KM, Parpinel M, Pekmezovic T, Riise T, Wolfson D, Zhu B, Wolfson C (2015) The EnvIMS study: design and methodology of an international case-control study of environmental risk factors in multiple sclerosis. Neuroepidemiology 44(3):173–181. https://doi.org/10.1159/000381779 Google Scholar
- 16.Xia Z, White CC, Owen EK, Von Korff A, Clarkson SR, McCabe CA, Cimpean M, Winn PA, Hoesing A, Steele SU, Cortese IC, Chitnis T, Weiner HL, Reich DS, Chibnik LB, De Jager PL (2016) Genes and Environment in Multiple Sclerosis project: a platform to investigate multiple sclerosis risk. Ann Neurol 79(2):178–189. https://doi.org/10.1002/ana.24560 Google Scholar
- 19.Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. https://doi.org/10.1002/ana.22366 Google Scholar
- 20.Dolic K, Weinstock-Guttman B, Marr K, Valnarov V, Carl E, Hagemeier J, Brooks C, Kilanowski C, Hojnacki D, Ramanathan M, Zivadinov R (2011) Risk factors for chronic cerebrospinal venous insufficiency (CCSVI) in a large cohort of volunteers. PLoS One 6(11):e28062. https://doi.org/10.1371/journal.pone.0028062 Google Scholar
- 21.Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452Google Scholar
- 23.Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–1847Google Scholar
- 24.Mukhopadhyay S, Fellows K, Browne RW, Khare P, Krishnan Radhakrishnan S, Hagemeier J, Weinstock-Guttman B, Zivadinov R, Ramanathan M (2017) Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. Mult Scler 23(6):792–801. https://doi.org/10.1177/1352458516666187 Google Scholar
- 25.Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17(1):479–489Google Scholar
- 32.Belov P, Jakimovski D, Krawiecki J, Magnano C, Hagemeier J, Pelizzari L, Weinstock-Guttman B, Zivadinov R (2018) Lower arterial cross-sectional area of carotid and vertebral arteries and higher frequency of secondary neck vessels are associated with multiple sclerosis. Am J Neuroradiol 39(1):123–130. https://doi.org/10.3174/ajnr.A5469 Google Scholar
- 35.Marck CH, Neate SL, Taylor KL, Weiland TJ, Jelinek GA (2016) Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors. PLoS One 11(2):e0148573. https://doi.org/10.1371/journal.pone.0148573 Google Scholar
- 36.Moon SY, de Souto Barreto P, Rolland Y, Chupin M, Bouyahia A, Fillon L, Mangin JF, Andrieu S, Cesari M, Vellas B, Group MDS (2018) Prospective associations between white matter hyperintensities and lower extremity function. Neurology 90(15):e1291–e1297. https://doi.org/10.1212/WNL.0000000000005289 Google Scholar
- 37.Srinivasa RN, Rossetti HC, Gupta MK, Rosenberg RN, Weiner MF, Peshock RM, McColl RW, Hynan LS, Lucarelli RT, King KS (2016) Cardiovascular risk factors associated with smaller brain volumes in regions identified as early predictors of cognitive decline. Radiology 278(1):198–204. https://doi.org/10.1148/radiol.2015142488 Google Scholar
- 40.Jacobsen C, Hagemeier J, Myhr KM, Nyland H, Lode K, Bergsland N, Ramasamy DP, Dalaker TO, Larsen JP, Farbu E, Zivadinov R (2014) Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 85(10):1109–1115. https://doi.org/10.1136/jnnp-2013-306906 Google Scholar
- 42.Moccia M, Lanzillo R, Palladino R, Maniscalco GT, De Rosa A, Russo C, Massarelli M, Carotenuto A, Postiglione E, Caporale O, Triassi M, Brescia Morra V (2015) The Framingham cardiovascular risk score in multiple sclerosis. Eur J Neurol 22(8):1176–1183. https://doi.org/10.1111/ene.12720 Google Scholar
- 43.Zivadinov R, Jakimovski D, Gandhi S, Ahmed R, Dwyer MG, Horakova D, Weinstock-Guttman B, Benedict RR, Vaneckova M, Barnett M, Bergsland N (2016) Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother 16(7):777–793. https://doi.org/10.1080/14737175.2016.1181543 Google Scholar
- 44.Dwyer MG, Silva D, Bergsland N, Horakova D, Ramasamy D, Durfee J, Vaneckova M, Havrdova E, Zivadinov R (2017) Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin 15:769–779. https://doi.org/10.1016/j.nicl.2017.06.022 Google Scholar
- 45.Zivadinov R, Bergsland N, Korn JR, Dwyer MG, Khan N, Medin J, Price JC, Weinstock-Guttman B, Silva D, Group M-MS (2018) Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in patients with relapsing-remitting MS. Am J Neuroradiol 39(2):289–295. https://doi.org/10.3174/ajnr.A5442 Google Scholar
- 46.Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott C, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O, group Ms (2018) Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 83(2):210–222. https://doi.org/10.1002/ana.25145 Google Scholar